# EXELIXIS, INC.

Summary updated: 2026-10-02T12:31:19.081544Z
Canonical: https://finbar.com/research/companies/exelixis-inc

## Overview

Exelixis, Inc. is a biotechnology company focused on discovering, developing, and commercializing cancer medicines, including small-molecule drugs and biotherapeutics. Its stated mission is to help cancer patients “recover stronger and live longer.” [1](https://app.finbar.com/go?id=P7155627)[2](https://www.exelixis.com/inside-exelixis/)

Its marketed portfolio includes CABOMETYX and COMETRIQ, both based on cabozantinib, as well as COTELLIC and MINNEBRO. Cabozantinib is the company’s principal commercial product, with approvals in the United States and 68 other countries; partners support commercialization in international markets. [3](https://app.finbar.com/go?id=P50614657)[4](https://app.finbar.com/go?id=P116640056)[5](https://app.finbar.com/go?id=P14725352)

Exelixis reported fiscal 2025 revenue of $2.320 billion. [6](https://app.finbar.com/go?id=T8702646) The company reported 1,077 employees as of December 31, 2025, and is headquartered in Alameda, California. [7](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)[8](https://www.exelixis.com/contact-us/)
[1](https://app.finbar.com/go?id=P7155627)[2](https://www.exelixis.com/inside-exelixis/)[3](https://app.finbar.com/go?id=P50614657)[4](https://app.finbar.com/go?id=P116640056)[5](https://app.finbar.com/go?id=P14725352)[6](https://app.finbar.com/go?id=T8702646)[7](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)[8](https://www.exelixis.com/contact-us/)[2](https://www.exelixis.com/inside-exelixis/)[7](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)[8](https://www.exelixis.com/contact-us/)

## Products & services

Exelixis’ marketed products are CABOMETYX® (cabozantinib) tablets and COMETRIQ® (cabozantinib) capsules. CABOMETYX is a multiple-tyrosine-kinase inhibitor, including activity against MET, AXL, VEGF receptors and RET. Its approved uses include advanced renal cell carcinoma (RCC), as monotherapy or with nivolumab; previously treated hepatocellular carcinoma (HCC); previously treated radioactive-iodine-refractory differentiated thyroid cancer (DTC); and previously treated, unresectable or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET/epNET). [3](https://app.finbar.com/go?id=P50614657)[9](https://app.finbar.com/go?id=T10540528)

COMETRIQ is approved for progressive, metastatic medullary thyroid cancer (MTC); the cited report also lists an indication for progressive, unresectable locally advanced or metastatic MTC in the EEA and U.K. Exelixis reports that cabozantinib product sales account for the majority of its revenue. [3](https://app.finbar.com/go?id=P50614657)[9](https://app.finbar.com/go?id=T10540528)
[3](https://app.finbar.com/go?id=P50614657)[9](https://app.finbar.com/go?id=T10540528)

## Geographic presence

Exelixis’ principal operating base is in Alameda, California, where its headquarters and main disclosed office and laboratory campus occupy approximately 610,000 square feet. Its principal executive offices are at 1851 Harbor Bay Parkway, Alameda. [10](https://app.finbar.com/go?id=P58359394)[11](https://app.finbar.com/go?id=P96829965)

The company’s disclosed product-sales revenue is primarily U.S.-based: it calculates gross product revenue from prices charged to specialty pharmacies and distributors in the United States. For 2025, it reported $2.123 billion in net product revenue, but did not provide a country- or region-level revenue breakdown or percentages. [12](https://app.finbar.com/go?id=P80037108)[13](https://app.finbar.com/go?id=P66553657)

Exelixis also has international royalty-generating markets. CABOMETYX was commercially available in 68 countries outside the United States at December 31, 2025. Exelixis reported $165.9 million in 2025 royalties from Ipsen, principally tied to cabozantinib sales outside the United States and Japan, and receives royalties on sales in Japan through its Takeda collaboration; Japan revenue was not separately quantified. [14](https://app.finbar.com/go?id=P62506635)[15](https://app.finbar.com/go?id=P121459967)

The company also disclosed office and laboratory space in Greater Philadelphia, but exited approximately 40,000 square feet there during 2025 and closed its King of Prussia, Pennsylvania office as part of a reorganization. The available reporting does not specify employee distribution by location. [16](https://app.finbar.com/go?id=P79530935)[17](https://app.finbar.com/go?id=P66497232)
[10](https://app.finbar.com/go?id=P58359394)[11](https://app.finbar.com/go?id=P96829965)[12](https://app.finbar.com/go?id=P80037108)[13](https://app.finbar.com/go?id=P66553657)[14](https://app.finbar.com/go?id=P62506635)[15](https://app.finbar.com/go?id=P121459967)[16](https://app.finbar.com/go?id=P79530935)[17](https://app.finbar.com/go?id=P66497232)

## Business segments

Exelixis reports one business segment: the discovery, development and commercialization of medicines for difficult-to-treat cancers. Product and collaboration revenues are revenue categories within this segment, not separately reported business segments. [18](https://app.finbar.com/go?id=P92736811)[19](https://app.finbar.com/go?id=P147123608)

As a breakdown of revenue rather than segments, net product revenues accounted for approximately 91.5% of FY2025 revenue, with collaboration revenues contributing 8.5%. For the first half of 2026, net product revenues were approximately 91.0% and collaboration revenues 9.0%. [13](https://app.finbar.com/go?id=P66553657)[20](https://app.finbar.com/go?id=P147123547)
[18](https://app.finbar.com/go?id=P92736811)[19](https://app.finbar.com/go?id=P147123608)[13](https://app.finbar.com/go?id=P66553657)[20](https://app.finbar.com/go?id=P147123547)

## Company history

Exelixis traces its founding to 1994, when its founders set out to apply genetics in model organisms to drug discovery. Stelios Papadopoulos was a co-founder, and George Scangos helped establish the company before becoming its president and CEO in 1996. Exelixis completed its initial public offering in 2000, raising $118 million and listing on Nasdaq. [21](https://www.exelixis.com/our-story/)[22](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-george-scangos-phd-retire-its-board-directors)[23](https://ir.exelixis.com/news-releases/news-release-details/exelixis-raises-118-million-initial-public-offering-common-stock)

In 2002, Exelixis entered a broad drug-discovery and development alliance with GlaxoSmithKline. Michael Morrissey succeeded Scangos as president and CEO in July 2010. A key shift toward commercial medicines followed: the FDA approved cabozantinib as COMETRIQ in 2012 for progressive, metastatic medullary thyroid cancer, its first major cabozantinib approval. [24](https://ir.exelixis.com/static-files/4688d9e8-5403-4855-82ad-f165b3a67e3e)[25](https://www.sec.gov/Archives/edgar/data/939767/000119312510153655/dex991.htm)[26](https://app.finbar.com/go?id=P115201589)

In 2016, the FDA approved CABOMETYX for previously treated advanced renal-cell carcinoma, and Exelixis launched it in the United States; that year, the company also partnered with Ipsen on cabozantinib commercialization outside the United States and Japan. Exelixis later extended the drug’s use to additional cancers, including pancreatic and extra-pancreatic neuroendocrine tumors, for which the FDA approved CABOMETYX in 2025. [27](https://app.finbar.com/go?id=P1299743)[28](https://app.finbar.com/go?id=P58662927)[29](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet)
[21](https://www.exelixis.com/our-story/)[22](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-george-scangos-phd-retire-its-board-directors)[23](https://ir.exelixis.com/news-releases/news-release-details/exelixis-raises-118-million-initial-public-offering-common-stock)[24](https://ir.exelixis.com/static-files/4688d9e8-5403-4855-82ad-f165b3a67e3e)[25](https://www.sec.gov/Archives/edgar/data/939767/000119312510153655/dex991.htm)[26](https://app.finbar.com/go?id=P115201589)[27](https://app.finbar.com/go?id=P1299743)[28](https://app.finbar.com/go?id=P58662927)[29](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet)[21](https://www.exelixis.com/our-story/)[22](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-george-scangos-phd-retire-its-board-directors)[23](https://ir.exelixis.com/news-releases/news-release-details/exelixis-raises-118-million-initial-public-offering-common-stock)[24](https://ir.exelixis.com/static-files/4688d9e8-5403-4855-82ad-f165b3a67e3e)[25](https://www.sec.gov/Archives/edgar/data/939767/000119312510153655/dex991.htm)[29](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet)

## Sources

1. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P7155627)
2. [www.exelixis.com](https://www.exelixis.com/inside-exelixis/)
3. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P50614657)
4. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P116640056)
5. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P14725352)
6. [EXELIXIS, INC. — Press release (2025 Y)](https://app.finbar.com/go?id=T8702646)
7. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)
8. [www.exelixis.com](https://www.exelixis.com/contact-us/)
9. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10540528)
10. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P58359394)
11. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P96829965)
12. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P80037108)
13. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P66553657)
14. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P62506635)
15. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121459967)
16. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P79530935)
17. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P66497232)
18. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P92736811)
19. [EXELIXIS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147123608)
20. [EXELIXIS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147123547)
21. [www.exelixis.com](https://www.exelixis.com/our-story/)
22. [ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-george-scangos-phd-retire-its-board-directors)
23. [ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-raises-118-million-initial-public-offering-common-stock)
24. [ir.exelixis.com](https://ir.exelixis.com/static-files/4688d9e8-5403-4855-82ad-f165b3a67e3e)
25. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/939767/000119312510153655/dex991.htm)
26. [EXELIXIS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P115201589)
27. [EXELIXIS, INC. — Full financial report (2016 Y)](https://app.finbar.com/go?id=P1299743)
28. [EXELIXIS, INC. — Full financial report (2016 Y)](https://app.finbar.com/go?id=P58662927)
29. [www.fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.